JNS.jpgThe October issue of the Journal of the Neurological Sciences Vol 381 is now available online.

 

Click here to access.

 

 

Issue highlights

alt="Abstract"

Neuroimaging and cognitive functions in temporal lobe epilepsy: A review of the literature

Temporal lobe epilepsy (TLE) is the most common form of refractory focal epilepsy.

This review investigated the state of research regarding neuropsychological impairment and neuroimaging studies in TLE patients. Results showed significant alterations in multiple cognitive domains, particularly memory, executive functions and language. The reported findings showed that the involvement of various factors, including neurobiological abnormalities and clinical features, is responsible for the onset of cognitive impairment in epileptic patients.

 

alt="Abstract"

The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis

The clinical aim was to provide up-to-date evidence-based recommendations for the treatment of MS-related fatigue (MSRF). The scientific aim was to prioritise topics for future randomised clinical trials with sufficient power.

  • No pharmacological interventions had strong evidence for improving Multiple Sclerosis related fatigue (MSRF).
  • Non-pharmacological interventions found mixed conclusions on MSRF.
  • Educational and exercise interventions had supporting evidence for reducing MSRF.
  • Yoga, energy conservation and fatigue management had strong evidence reducing MSRF.

 

alt="Abstract"

Cerebral hyperperfusion syndrome and intracranial hemorrhage after carotid endarterectomy or carotid stenting: A meta-analysis

  • CEA seems to be associated with a higher risk for CHS compared to CAS.
  • This association seems to be generated mainly from the older studies.
  • There seems to be no difference regarding ICH risk between the two methods.
  • ICH is associated with a significantly higher risk for death.

 

alt="Abstract"

Follow-on products for treatment of multiple sclerosis in Latin America: An update

  • Economic pressures are the major driving force for development of follow-on products.
  • High-quality medicines are essential to ensure optimal clinical impact for patients.
  • Small molecule follow-on products must demonstrate pharmaceutical equivalence.
  • To show therapeutic equivalence biosimilars required comparability clinical studies.
  • Pharmacovigilance programs for copies are not enforced in many LATAM countries.